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Abstract
Background Opioid overdose is a major and increasing
cause of injury and death. There is an urgent need for
interventions to reduce overdose events among high-risk
persons.
Methods Adults at elevated risk for opioid overdose
involving heroin or pharmaceutical opioids who had
been cared for in an emergency department (ED) were
randomised to overdose education combined with a
brief behavioural intervention and take-home naloxone
or usual care. Outcomes included: (1) time to first opioid
overdose-related event resulting in medical attention or
death using competing risks survival analysis; and (2) ED
visit and hospitalisation rates, using negative binomial
regression and adjusting for time at risk.
Results During the follow-up period, 24% of the 241
participants had at least one overdose event, 85%
had one or more ED visits and 55% had at least one
hospitalisation, with no significant differences between
intervention and comparison groups. The instantaneous
risk of an overdose event was not significantly lower for
the intervention group (sub-HR: 0.83; 95% CI 0.49 to
1.40).
Discussion These null findings may be due in part
to the severity of the population in terms of housing
insecurity (70% impermanently housed), drug use,
unemployment and acute healthcare issues. Given the
high overdose and healthcare utilisation rates, more
intensive interventions, such as direct referral and
provision of housing and opioid agonist treatment
medications, may be necessary to have a substantial
impact on opioid overdoses for this high-acuity
population in acute care settings.
Trial registration number NCT0178830; Results.
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Opioid overdose deaths continue to increase and
are a major cause of preventable death.1 According
to the CDC, opioid-involved overdose deaths
quadrupled from 1999 to 2015 when there were
33 091 such deaths in the USA.2 Additionally,
opioid-related emergency department (ED) visits
and inpatient admissions have increased dramatically over the years reflecting the increase in
non-fatal overdose.3 Many overdoses are amenable
to intervention due to biological and social circumstances.4 Opioid overdoses rarely lead to sudden
death, with death usually occurring several hours
after consumption,5 though this may be changing
as illicit synthetic opioids with their rapid rates of

onset and high potency emerge as major causes
of death.6 Moreover, most overdoses occur in the
presence of another person,7 8 providing an opportunity for bystander intervention.
Brief behaviour change counselling is based on
motivational interviewing (MI),9 has been found
to help reduce drug use frequency10 and to significantly improve health behaviours such as alcohol
use and injury, to increase entry into drug abuse
treatment and to reduce costs in ED.11 12 In pharmaceutical opioid using patients in the ED with
elevated risk for overdose, patients receiving a brief
behavioural intervention had decreased overdose
risk behaviours.13 Additionally, brief intervention
has been used to decrease drug use among patients
in the ED.14 However, these studies did not specifically target illicit opioid use and did not combine
brief behaviour change counselling with takehome naloxone. We combined these interventions
based on the information–motivation–behaviour
model, positing that overdose education, combined
with self-identified motivating factors and the
behavioural skills to utilise naloxone, might impact
overdose occurrence.15
Naloxone is an opioid-antagonist prescription
medication that reverses opioid overdoses by preferentially binding to opioid receptors and displacing
opioids such as heroin, morphine, oxycodone
and fentanyl and reversing respiratory depression
and sedation. Naloxone cannot be abused, has
no psychoactive effects and has been found to be
extremely safe.16 17 Since the 1990s, naloxone has
increasingly been provided to people who use drugs
through low-threshold service programmes such
that by 2014 community-based programmes were
distributing naloxone to laypersons at 644 sites
in the USA.18 Take-home naloxone for lay people
has been recommended by organisations such as
the WHO and in the Substance Abuse and Mental
Health Services Administration opioid overdose
toolkit.19 20
Research on take-home naloxone provided to
people at risk for having or witnessing an overdose
indicates that: (1) naloxone administration has not
resulted in dangerous health consequences21; (2)
lay persons can be trained to recognise an overdose
and evaluate whether administration of naloxone
is warranted as well as medical experts22; (3) illicit
drug users are willing to administer naloxone to
each other23; (4) naloxone availability does not
increase drug use24; (5) many opioid overdoses
have been reversed with naloxone as a result of

Banta-Green CJ, et al. Inj Prev 2019;25:191–198. doi:10.1136/injuryprev-2017-042676

191

Inj Prev: first published as 10.1136/injuryprev-2017-042676 on 7 February 2018. Downloaded from http://injuryprevention.bmj.com/ on 16 August 2019 at Portland State University
Library-Serials. Protected by copyright.

Impacts of an opioid overdose prevention
intervention delivered subsequent to acute care
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Methods
Setting

Participants were enrolled subsequent to a visit at one of two
EDs in Seattle: Harborview Medical Center (HMC) and the
University of Washington Medical Center (UWMC). HMC is
a large urban academic medical centre dedicated to an underserved population including those with mental health and
substance use problems. UWMC is an academic tertiary care
hospital providing extensive specialty care. Potential participants
were identified through medical records review by study staff or
healthcare staff referrals. Recruitment and enrolment generally
occurred between the hours of 12:00 and 20:00 weekdays in the
ED, in other hospital units during subsequent inpatient admission or at respite care (a recuperative care facility adjacent to
HMC for homeless people who require medical assistance and
shelter and do not require inpatient treatment).

Participants

Potential participants were identified either by study staff
reviewing electronic medical records or by medical staff referral
with eligibility confirmed via a screening questionnaire. Eligibility criteria included being at elevated risk of opioid overdose
based on: (1) reason for visit was opioid overdose; (2) use of
pharmaceutical opioids not prescribed two or more times in the
prior month; (3) use of other opioids, alcohol, sedatives or stimulants within 2 hours of using opioids two or more times in the
prior month; (4) average daily dose of prescribed opioids greater
than 10 mg morphine equivalent dose or higher for 15 or more
of the last 30 days; or (5) enrolled in an opioid agonist therapy
(OAT) programme and receiving methadone or buprenorphine.
Opioids needed to be used at least twice in the last 30 days (or
if institutionalised recently, in the most recent month they were
not institutionalised) with pharmaceutical users also needing
to have other risks present. Subjects were not excluded if pregnant and were offered naloxone if in the intervention arm and
informed during consent about potential risks to a fetus due to
precipitated withdrawal and the need to seek emergency medical
care.
Exclusion criteria included: (1) refusing access to follow-up
medical or drug treatment records; (2) inability to communicate
in English; (3) current suicidal ideation; (4) significant cognitive or psychiatric impairment; (5) inability to provide adequate
contact information to assist with follow-up (the number of
192

required contacts was reduced after a month of recruitment from
three to one as most homeless people were being excluded that
would have negatively impacted the generalisability of the findings); (6) under age 18 years or over age 70 years; (7) not living
in Washington State or planning to move from Washington State
within a year; (8) receiving treatment for sexual assault; or (9)
currently having non-expired naloxone.
Potential participants provided informed consent for eligibility screening. If eligible and interested in the study, consent
was obtained for study participation. Eligibility screening and
study participation were remunerated with $5 and $20 store gift
cards, respectively. Follow-up surveys were conducted at 3, 6
and 12 months (with $10, $10 and $20 gift card remunerations,
respectively); these data are not presented here as follow-up
rates were below 50% at each time point. Releases of information and HIPAA (Health Insurance Portability and Accountability
Act) authorisations were obtained to access medical records and
drug treatment data. Baseline data were collected by interventionists in clinical settings, with an attempt to maximise privacy,
and participants were randomised; this process took approximately 30–45 min. An unrestricted or ‘fair-coin’ randomisation
process was used to generate a study assignment table based on
study identification numbers and implemented automatically via
Research Electronic Data Capture (REDCap) with interventionists learning study assignment at the same time as the participant.
Study data were collected and managed using REDCap electronic data capture, secure web-based tools hosted at the Institute
of Translational Health Sciences at the University of Washington.

Intervention

The intervention consisted of (1) overdose education, (2) a brief
behavioural change counselling component to assist participants in identifying their overdose risks and the steps they were
interested in taking to reduce those risks and (3) a naloxone kit.
The intervention was provided by two interventionists who had
master’s degree and at least basic training in MI.
Overdose education included watching an 8 min video and
reviewing an informational flier with the interventionist, which
addressed risk factors for an opioid overdose, overdose recognition, recommendation to call 911, how to administer naloxone
and guidance to remain with the overdose victim for several
hours. The flier also provided specific information about locations where naloxone could be obtained either free at area
syringe exchange programmes or for purchase at a local pharmacy. The flier included a link to www.stopoverdose.org, which
has online overdose educational materials, including the training
video used at the time created by the New York City Department
of Health as well as a naloxone locator for Washington State.
Naloxone administration training included hands-on practice
assembling the kit,which included a luer lock syringe, 2 mg/2 mL
naloxone (Amphastar NDC#76329-3369-1) and a mucosal
atomisation device. Intranasal administration was an off-label
route of administration, and a Food and Drug Administration
Investigational New Drug application was required (#112 043).
The kit included two doses of naloxone, two mucosal atomisers,
a disposable rescue breathing mask, a wallet card with information about Washington State’s Good Samaritan Overdose and
naloxone access law (RCW 69.50.315) and the educational flier
all packaged in a nylon pouch. Participants were directly handed
the kit by study staff; however, they did not need to accept the
offer of the kit to be considered a study participant.
Participants assigned to the comparison group were provided
the informational flier.
Banta-Green CJ, et al. Inj Prev 2019;25:191–198. doi:10.1136/injuryprev-2017-042676
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overdose prevention and recognition training combined with
the distribution of take-home naloxone25; and (6) provision
of naloxone is associated with reduced mortality in communities that implement the programme compared with communities that do not and reduced opioid overdose mortality after
release from prison.25 26 However, there are no trials that aim
to assess the impact of pairing naloxone provision with a brief
behavioural intervention in healthcare settings on subsequent
overdose events and healthcare utilisation.
ED and acute care settings are potentially advantageous
settings to reach populations vulnerable to opioid overdose that
may not access healthcare in other settings such as substance
use disorder treatment centres or primary care. In this study, we
tested an intervention for opioid users at elevated risk for overdose that was delivered during or after an acute care episode that
combined opioid overdose education, a take-home naloxone kit
and brief behaviour change counselling to determine the impact
on participants’ subsequent opioid overdoses, ED visits and
hospitalisations.

Original article

Intervention fidelity

Sessions were audio-recorded, and initial training and regular
supervision with a doctoral level psychologist (CD) occurred
throughout the study. A sample of intervention recordings were
reviewed for fidelity. The intervention was MI)inspired in order
to facilitate rapport building and participant engagement. Despite
not being a full MI intervention, given the didactic and interactive educational components, fidelity was measured using scales
from the Motivational Interviewing Treatment Integrity 3.1.1.
Interventionist behavioural counts were measured along with MI
Spirit, an average measure of the quality of MI delivery.27

Data sources

The baseline survey included demographic information, housing
status and relationship status. Opioid use in the prior 30 days was
categorised as: only pharmaceutical opioids whether prescribed
to the participant or not, OAT from an approved provider (licit
source), heroin and OAT, and OAT no heroin. Route of administration was coded into whether a person had smoked, snorted or
injected any opioids (96% reported injecting). Days of opioid use
in the prior 30 days was recorded. Protective factors, including
whether ‘anyone you have regular contact with’ had ‘overdose
education’ or ‘regularly carry or have quick access to naloxone’,
were documented. Overdose risk factors included: overdose
history; using opioids when no one else was around or behind
a locked door; and using opioids within 2 hours of alcohol,
sedatives/downers (specific brand names were provided), using
Banta-Green CJ, et al. Inj Prev 2019;25:191–198. doi:10.1136/injuryprev-2017-042676

another kind of opioid or stimulants including cocaine, methamphetamine or pharmaceutical stimulants.
Healthcare utilisation data from UW Medicine included
encounter and billing data from HMC and UWMC, their EDs
and affiliated onsite and offsite clinics in the Seattle, Washington,
metropolitan area.
The Comprehensive Hospital Abstract Reporting System
(CHARS) maintained by the Washington State Department of
Health was used for statewide capture of opioid overdose events
resulting in inpatient or hospital observation stays. CHARS
contains hospital discharge information for inpatient and observation stays derived from billing records for essentially all Washington State community hospitals. Statewide death certificate
data were obtained from the Washington State Department of
Health.

Outcome measures

ED visits were defined as an encounter that had at least one
charge originating from the ED, regardless of whether it resulted
in inpatient admission. Some encounters may have been counted
as both an ED visit and an inpatient admission, but each metric
was analysed separately. Index encounters were defined as ED
visits or inpatient admissions (1) beginning on or before the
randomisation date and (2) concluding on or after the randomisation date. ED visits and inpatient admissions were counted
separately and included all encounters for any principal diagnosis
with admission/visit dates occurring after the discharge date of
193
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Figure 1 CONSORT diagram, study enrolment, allocation and analysis. CONSORT, Consolidated Standards of Reporting Trials.

Original article
Participant demographic characteristics, opioid use patterns, overdose history and risk and protective factors

Age mean SD

Intervention

Comparison

Total

n=115

n=126

n=241

40.2

11.5

n

%

42.3

11.5

n

%

41.3

11.5

n

%

Female

32

28

37

29

69

29

Hispanic

14

12

21

17

35

15

Race
 White

60

53

67

54

127

53

 Black

17

15

14

11

31

13

 Asian

0

0

2

2

2

1

 Hawaiian/Pacific Islander

0

0

2

2

2

1

 American Indian/Native Alaskan

6

5

6

5

12

5

 Other

13

11

14

11

27

11

 More than one race

18

16

19

15

37

16

 Permanent

29

25

44

35

73

30

 Impermanent

19

17

22

18

41

17

 Homeless

67

58

59

47

126

53

38

33

35

28

73

30

37

32

45

36

82

34

40

35

46

37

86

36

Housing

Education
<High School
 High School
>High School
Relationship
 Not in a relationship

86

75

83

66

169

71

 In a relationship

28

25

42

34

70

29

Employment
9

8

9

7

18

8

88

77

88

70

176

73

 Retired

6

5

4

3

10

4

 Unable to work

7

6

22

18

29

12

 Other*

5

4

2

2

7

3

 Pharmaceutical only

18

16

13

10

31

13

 Heroin and no opioid agonist therapy

67

58

74

59

141

59

 Heroin and opioid agonist therapy

24

21

24

19

48

20

 Opioid agonist therapy no heroin

6

5

15

12

21

9

Smoke/snort/inject opioids

94

82

101

80

195

81

# of days used opioids past
30 days mean SD

24.3

 Employed
 Unemployed

Opioid type

8.4

25.1

8.8

24.7

8.6

Know others with overdose education
 Yes

45

39

62

49

107

44

 No/do not know

69

60

64

51

133

55

 Yes

33

29

41

33

74

31

 No/do not know

82

71

85

67

167

69

Know others who have naloxone

Opioid overdose history
 Never overdosed

48

42

56

44

104

43

 Overdosed, not past 3 months

48

42

43

34

91

38

 Overdosed past 3 months

19

17

27

21

46

19

Used alone past 3 months

89

77

100

79

189

78

 Alcohol

36

31

54

43

90

37

 Sedatives/downers

48

42

61

48

109

45

Always/sometimes use ___ within 2 hours of opioids

 More than one kind of opioid

53

46

54

43

107

44

 Uppers: cocaine, methamphetamine, pharmaceutical

57

50

72

57

129

54

194
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Opioid overdose events and censoring by randomisation status
Opioid overdose event status by data source: n (%)

Group

Total N

First opioid
overdose in UW
Medicine*

First opioid
overdose in
CHARS†

First opioid
overdose fatality
in DOH‡

Non-overdose
fatality in DOH‡

No event prior to
censoring at study Mean days to first
overdose event¶
end§

Comparison group

126

21 (16.7)

6 (4.8)

6 (4.8)

7 (5.6)

86 (68.3)

836

Intervention group

115

18 (15.7)

4 (3.5)

2 (1.7)

8 (7.0)

83 (72.2)

870

Combined

241

39 (16.2)

10 (4.2)

8 (3.3)

15 (6.2)

169 (70.1)

852

*Local inpatient admission or emergency department visit.
†Statewide hospital discharge for inpatient admission or observation visit.
‡Death certificate data, Department of Health.
§Available follow-up time: 272–1064 days.
¶Mean is underestimated because the largest observed analysis time is censored.
CHARS, Comprehensive Hospital Abstract Reporting System; UW, University of Washington.

the index visit through 31 December 2015. Index encounters
were excluded from outcome encounter counts and excluded
from consideration as the first opioid overdose event (described
below), because the need for these encounters was evidenced
prior to the intervention and hence not properly considered an
outcome.
All three administrative data sources (ie, UW Medicine,
CHARS and death certificate data) were used jointly to identify the first opioid overdose event occurring after randomisation and discharge from the index encounter and censored at
31 December 2015. Time to the first opioid overdose event was
measured from randomisation to the date of the first-occurring
qualifying event: (1) UW Medicine ED, inpatient or outpatient
encounter for opioid overdose, (2) CHARS inpatient admission or observation stay for opioid overdose or (3) death from
opioid overdose. The definitions for an opioid overdose based
on ICD-9 (International Classification of Diseases) and ICD-10
codes across datasets are detailed in the online supplement.

Sample size

Power calculations were based on the estimated annual overdose
rate of 20% for heroin users and 10% for pharmaceutical opioid
users (seen in the ED) and reduction in opioids overdoses of 50%
due to the intervention. The sample size for heroin users to meet
these parameters was 219 with 1 year of follow-up for overdose.
For pharmaceutical users with an estimated annual overdose rate
of 10%, we would require roughly twice the number of subjects
or double the follow-up time to have the same number of overdose events.

Data analysis

Healthcare utilisation outcomes (ie, number of ED visits and
number of inpatient admissions) were analysed using negative
binomial regression with robust variance estimates and a time
Table 3

at-risk exposure adjustment for available follow-up time. Mean
rates per person-year were calculated using these models.
Kaplan-Meier survival function curves were used to depict
time from randomisation to the first opioid overdose event,
with days of follow-up as the time scale. Death due to causes
other than opioid overdose was treated as a censoring event but
cannot be considered independent of randomisation assignment.
We therefore treated death due to causes other than opioid overdose as a competing risk, using competing risk survival analysis
models to analyse time from randomisation to the first opioid
overdose event.28 The STATA command -stcrreg- (based on the
Fine and Gray semiparametric method) was used to produce
sub-HRs (SHR).29 30
All statistical tests were two tailed, with statistical significance
defined as P≤0.05. Analyses were performed using Stata/MP
V.13.1 for Windows. The study was registered at clinicaltrials.
gov (NCT01788306).

Results
Study enrolment

Enrollment occurred between 31 January 2013 and 3 April
2015, allowing for at least 272 and up to 1064 days of follow-up,
which ended on 31 December 2015. Participant enrolment, allocation and analysis are outlined in the Consolidated Standards of
Reporting Trials (CONSORT) diagram in figure 1, as are reasons
for study exclusion. Among the 430 assessed for study eligibility,
256 were enrolled and randomised, with 125 allocated to the
intervention and 131 to the comparison group.
The study underenrolled compared with the original study
design of 500 heroin and 500 pharmaceutical opioid users.
The randomisation process appears to have achieved sufficient
balance; baseline characteristics in table 1 are comparable (all
P values >0.05). For these analyses only those who provided
consent to access secondary data were included: 115 in the

Annual local healthcare utilisation (all cause) after study enrolment by randomisation status
Emergency department visits*

Inpatient admissions

Group

Median annual
rate
IQR

Mean annual
rate†

95% CI

Median annual
rate

IQR

Mean annual
rate†

Comparison group

2.72

5.49

95% CI

4.85

3.96 to 5.93

0.43

1.50

1.05

Intervention group

2.42

0.80 to 1.39

7.35

4.96

4.04 to 6.10

0.39

1.80

1.29

Combined

2.57

0.95 to 1.76

6.93

4.90

4.25 to 5.66

0.41

1.52

1.17

0.95 to 1.44

Note: r ate differences between the intervention and comparison groups were not statistically significant.
*Regardless of discharge status (may have resulted in inpatient admission).
†Mean rate per person-year calculated using negative binomial regression with time at-risk exposure variable for available follow-up time (272–1064 days, censored at death or
31 December 2015).
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The majority (55%) of all participants had a hospital admission
during the follow-up period with an average annual rate of 1.17
(95% CI 0.95 to 1.44) visits and with no significant difference
between the intervention and comparison groups (table 3). A
substantial majority (85%) of all participants had a subsequent
ED visit during the follow-up period, with an average annual
rate of 4.90 (95% CI 4.25 to 5.66) visits and with no significant
difference by intervention assignment.

Time to first overdose by intervention assignment

In the competing risk regression analysis, the difference in the
time to first overdose event was not significantly lower for the
intervention group relative to the comparison group (SHR: 0.83;
95% CI 0.49 to 1.40). These data are presented as a survival
curve in figure 2.
Figure 2 Time to the first opioid overdose event (encounter or death)
(n=241).

intervention arm and 126 in the comparison group, a combined
total of 241. The care setting in which participants were recruited
included ED (n=149), respite care (n=37) and hospital inpatient (n=55) and did not differ significantly by study assignment.
We identified potential subjects as quickly as possible and among
those enrolled in respite care 89% had their baseline assessment
completed within 3 days of starting the assessment (maximum 5
days) and among inpatients 98% had the assessment completed
within 2 days (maximum 3).

Characteristics of intervention and comparison groups
The majority of participants were male, white, non-Hispanic,
homeless, not in a relationship, unemployed, used heroin and
not in OAT and used opioids by routes of ingestion including
smoking, snorting or injecting (table 1). The mean number of
days that opioids were used in the past 30 days was 24.7 (8.6
SD) with a median of 30. Protective factors for overdose were
reported by a minority of participants including others in their
life having overdose education or possessing naloxone. The
majority had a history of an opioid overdose, 19% in the prior
3 months and 38% sometime prior to the most recent 3 months.
The vast majority, 78%, reported using opioids alone sometimes
or always in the prior 3 months, and many reported using a range
of other substances within 2 hours of using opioids. A substantial minority reported having had prior overdose education and
knowing others who had naloxone.

MI fidelity
MI Spirit was calculated on 61 intervention sessions (out of 76
recordings), with an average score of 4.23 (out of 5). Recorded
length across the 76 sessions for the overdose education and
brief behaviour change counselling content averaged 27 min,
with length ranging from 10 min to 55 min.

Overdose events by intervention assignment
Opioid overdose events and censoring by randomisation status
are presented in table 2 and indicate that 23.7% of participants had at least one overdose event of some type, 6.2% had a
non-overdose fatality and 70.1% had no observed event prior to
censoring at the end of study follow-up.
196

Discussion

In this study of patients at high risk for opioid overdose
presenting for or soon after emergency care, an overdose
prevention intervention was found to have no statistically
significant impact on subsequent overdoses, either positive
or negative. This null finding is perhaps not surprising given
the medical and social acuity of the population in terms of
homelessness, drug use and other health and social issues. A
brief, one-time intervention in acute care settings or subsequent to receiving acute care may not be sufficient to reduce
serious overdose events. The multipart intervention was likely
more intensive and time consuming than most overdose education and naloxone distribution programme in community or
medical settings, although there is great heterogeneity in these
interventions.
Population-based studies have found decreased mortality
rates associated with distributing naloxone to illicit drug
users.25 Estimates of the lifetime impact of naloxone distribution to individual heroin users are modest, a 6% mortality
reduction.31 Naloxone distribution programmes provide clear
life-saving benefits; however, they are also insufficient to
substantially address opioid overdose alone. Brief interventions in the ED have shown modest benefits in decreasing
opioid-related risk behaviours and drug use; however, these
studies were of those with recent prescription opioid misuse
and used a much broader definition of overdose that was not
limited to opioids.13 14 We did not use self-report of overdose
as an outcome as follow-up rates at each time point were less
than 50%, perhaps due to the high levels of housing impermanence. We chose to enrol a high-acuity population, despite
knowing that this might lessen the impact of the intervention
and lower follow-up rates as we felt it was important to enrol a
population representative of that seen in the care settings. It is
possible that the informational flyer provided to the comparison group combined with the substantial increases in takehome naloxone within the community was sufficient to reduce
any differential effect of the intervention.
The statistical power to detect differences was limited by
the sample size and given the modest, though significant,
impact of naloxone distribution found in other studies likely
was an important limitation in our ability to find any potential
impact of our intervention. We attempted to address this by
adding measures of non-fatal overdose as an outcome because
studies with an outcome of fatal overdose require sample
sizes of many thousands,26 but we could only capture overdose events that resulted in an outpatient visit, ED or hospital
Banta-Green CJ, et al. Inj Prev 2019;25:191–198. doi:10.1136/injuryprev-2017-042676
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What is already known on the subject
►► Opioid overdoses are increasing rapidly.
►► Overdose education and take-home naloxone decrease

population rates of overdose.

What this study adds
►► A brief behavioural-educational intervention combined with

an offer of naloxone did not reduce opioid overdose events
or health care utilisation among a high-acuity population
seen in postacute care.
►► Patients seen in acute care settings at elevated risk
for overdose had very high rates of subsequent
emergency department visits and hospitalisations and
warrant more intensive interventions.
►► Clinical trials of emergent issues may be impacted by rapid
changes in the public health and healthcare environments.
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